• 목록
• 답변

Arbormed announced on the 24th that it has signed a copyright contract for two complex generic drugs in the U.S. in order to explore the local drug market.
In addition to developing treatments for rare and incurable diseases, Arbormed is engaged in Complex Generic FDA approval and U.S. distribution business.

Apart from the existing rights to aseptic injections and skin patches obtained from domestic pharmaceutical companies, Arbormed has also secured the rights to peptide injections for the U.S., PTS's middle ear complex mucus, India's Etico's osteoporosis, and Pachet's disease.

Complex Generic refers to drugs with a limited number of cloned versions due to manufacturing and development difficulties, as well as drugs in specialized fields such as peptides and complexes of various raw materials, or those subject to strict manufacturing regulations like aseptic injections and anti-cancer injections. FDA-approved cloned drugs account for about 90% of prescription drugs prepared in the United States, making them a key area of focus in the pharmaceutical industry.

Arbormed official stated, 'Through our management's network, business development experience in the United States, and a team of experts, we have been able to source competitive medicines. We expect annual sales of 10 billion won through FDA approval in 2024 and subsequent sales in 2025.'"